No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
434 |
4. Check minimum number of eventsNone |
434 |
5. Include endpointsNone |
434 |
6. Filter based on genotype QC (FinnGen only) |
393 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L81
- Name in latin
- Purpura pigmentosa
Similar endpoints
↥List of similar endpoints to
Pigmented purpuric dermatosis
based on the number of shared cases.
Similar with more cases:
- Other disorders of pigmentation
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2176 | 1158 | 1011 |
| Only index persons | 2090 | 1132 | 958 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 59.25 | 60.79 | 57.46 |
| Only index persons | 59.00 | 60.61 | 57.08 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 393 | 225 | 168 |
| Unadjusted period prevalence (%) | 0.08 | 0.08 | 0.08 |
| Median age at first event (years) | 61.85 | 60.97 | 63.03 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 403
- Matched controls
- 4030
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L81.7
ICD-10 Finland
Pigmented purpuric dermatosis
+∞
307.7
403
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
10.4
93.8
125
167
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.5
45.2
157
500
D07AC01
ATC
betamethasone; topical
4.1
42.7
235
1030
D07AB02
ATC
hydrocortisone butyrate; topical
3.4
32.1
186
807
E0000UV, ,
ATC
3.3
30.4
236
1210
D07AB08
ATC
desonide; topical
3.8
20.9
74
228
D69.0
ICD-10 Finland
Allergic purpura
44.3
20.7
25
6
D07AD01
ATC
clobetasol; topical
3.1
19.6
99
380
D07AC13
ATC
mometasone; topical
2.7
19.0
155
768
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
198.9
18.7
19
*
D69.2
ICD-10 Finland
Other nonthrombocytopenic purpura
49.7
16.2
19
*
I83.9
ICD-10 Finland
Varicose veins of lower extremities without ulcer or inflammation
3.2
14.9
65
227
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
4.2
13.2
36
91
D02AX
ATC
Other emollients and protectives
5.6
12.9
25
47
I87.2
ICD-10 Finland
Venous insufficiency (chronic)(peripheral)
2.9
12.9
69
270
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.4
12.9
120
615
I83.1
ICD-10 Finland
Varicose veins of lower extremities with inflammation
9.4
12.4
25
28
H02AB06
ATC
prednisolone; systemic
2.1
11.5
217
1454
UJF32
NOMESCO Finland
Coloscopy
2.1
10.4
127
718
XQ848
NOMESCO Finland
Dermatological photography
4.9
10.4
23
49
S18
ICPC
Laceration/cut
2.0
10.3
215
1474
L17
ICPC
Foot/toe symptom/complaint
2.0
10.0
149
906
L30.0
ICD-10 Finland
Nummular dermatitis
4.0
10.0
29
77
S29
ICPC
Skin symptom/complaint other
2.2
9.3
99
528
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
2.5
9.3
64
283
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
9.1
107
593
S21
ICPC
Skin texture symptom/complaint
2.3
9.1
77
374
E000002, ,
ATC
2.7
9.1
51
204
L98.9
ICD-10 Finland
Disorder of skin and subcutaneous tissue, unspecified
19.1
9.0
13
7
E000001, ,
ATC
2.2
8.9
91
477
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
8.2
188
1297
R06AX27
ATC
desloratadine; oral
2.0
8.2
121
724
L82
ICD-10 Finland
Seborrhoeic keratosis
2.1
8.2
85
447
J01DB01
ATC
cefalexin; oral
2.2
8.0
340
2852
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.4
7.7
56
253
R06AE07
ATC
cetirizine; oral
1.8
7.5
181
1260
R23.8
ICD-10 Finland
Other and unspecified skin changes
2.0
7.4
99
570
S08
ICPC
Skin colour change
3.1
7.1
30
102
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
7.1
210
1542
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
2.9
7.1
34
125
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
3.3
7.0
26
82
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
6.9
62
307
L01BA01
ATC
methotrexate; systemic
4.2
6.9
18
44
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.8
6.8
131
847
XF404
NOMESCO Finland
Ambulatory ECG
2.5
6.7
45
196
R01AD58
ATC
fluticasone, combinations; nasal
1.9
6.7
103
620
K29.0
ICD-10 Finland
Acute haemorrhagic gastritis
23.0
6.7
9
*
J01MA02
ATC
ciprofloxacin; systemic
1.8
6.7
161
1110
N03AX12
ATC
[U] gabapentin; oral
2.0
6.6
80
444
A08
ICPC
Swelling
2.7
6.6
35
136
QDA99
NOMESCO Finland
Other local destruction of skin of lower limb
70.9
6.4
7
*
R42
ICD-10 Finland
Dizziness and giddiness
1.8
6.4
106
653
L15
ICPC
Knee symptom/complaint
1.8
6.4
117
744
WZC00
NOMESCO Finland
Treatment plan or consultation
1.7
6.3
153
1055
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
5.5
6.2
17
32
TQW80
NOMESCO Finland
Local dermatologic skincare
5.9
6.2
16
28
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
5.3
6.1
17
33
A02BC03
ATC
lansoprazole; oral
1.8
6.0
126
830
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
52
159
3.61
14.66
1.6
1.9
9.92
6.55
iu/ml
—
10
35
281
2088
2.14
11.05
13.1
9.7
4.12
4.11
e9/l
0.03
260
1815
234
1635
2.03
10.76
6.0
4.8
36.54
35.76
g/l
1.49
226
1549
71
313
2.54
10.42
2.6
3.5
67.27
66.91
g/l
0.13
64
290
19
36
5.49
9.73
1.3
1.1
104.00
68.00
titre
—
5
5
333
2703
2.34
9.68
6.5
4.3
12.74
12.23
mm/h
0.23
320
2502
337
2786
2.28
8.76
11.2
8.1
79.38
78.17
u/l
0.20
329
2632
232
1699
1.86
8.43
18.3
12.9
1.30
1.22
inr
1.22
196
1392
115
685
1.95
7.86
1.5
1.3
26.40
33.81
iu/ml
0.41
46
218
297
2381
1.94
7.84
5.5
4.7
380.80
1350.75
e6/l
—
5
40
186
1294
1.81
7.78
3.5
3.3
7.04
7.64
mmol/l
1.15
165
1073
85
463
2.06
7.43
2.6
1.9
—
—
—
0
0
386
3470
3.66
7.24
25.0
15.8
20.99
24.01
mg/l
1.18
338
2852
88
490
2.02
7.23
2.5
1.9
—
—
—
0
0
257
1995
1.80
7.20
5.3
3.9
0.00
0.79
estimate
0.51
46
391
80
431
2.07
7.19
5.6
7.3
1.54
0.83
mmol/l
1.25
67
361
180
1262
1.77
7.17
4.1
4.0
5.51
7.50
mg/mmol
0.54
102
763
253
1959
1.78
7.11
5.1
3.8
0.00
0.00
estimate
0.50
50
404
146
967
1.80
7.03
3.2
2.8
341.46
342.64
umol/l
0.05
127
836
254
1974
1.78
6.99
5.2
3.8
0.00
3.92
estimate
0.50
49
414
115
710
1.87
6.94
6.2
3.9
184.00
388.69
ng/l
0.68
98
568
226
1709
1.73
6.76
7.3
6.2
1.21
1.21
mmol/l
0.65
218
1576
222
1672
1.73
6.72
3.3
2.5
81.17
77.62
nmol/l
1.02
210
1496
269
2150
1.76
6.47
5.4
4.7
6.45
6.65
mmol/l
1.27
260
2045
219
1665
1.69
6.22
3.7
2.9
119.03
127.06
ug/l
0.31
206
1546
31
117
2.79
6.15
1.3
1.3
—
29.04
—
0
5
26
89
3.05
6.12
1.3
1.3
—
2.51
—
0
7
102
633
1.82
5.96
1.4
1.3
3.26
12.69
u/ml
2.60
40
240
32
125
2.69
5.95
2.7
3.0
—
—
—
0
0
177
1287
1.67
5.85
4.1
3.4
2.36
2.36
mmol/l
0.08
168
1165
240
1889
1.67
5.81
9.3
6.9
1.21
1.21
mmol/l
0.00
216
1635
102
645
1.78
5.56
2.5
1.9
—
—
—
0
0
80
474
1.86
5.38
6.4
5.1
1.08
1.03
mmol/l
0.67
75
438
319
2739
1.79
5.32
5.3
4.2
15.03
14.82
pmol/l
0.79
299
2490
245
1973
1.62
5.12
7.9
6.4
10.74
12.04
umol/l
1.36
239
1890
198
1519
1.60
5.05
2.2
1.9
1.36
1.36
mmol/l
0.00
173
1279
162
1189
1.61
4.95
3.6
3.1
2370.62
1056.59
ng/l
0.52
142
1013
88
551
1.76
4.91
2.3
1.8
29.46
29.08
s
0.28
83
538
20
67
3.09
4.90
1.1
1.5
—
—
—
0
0
20
67
3.09
4.90
1.1
1.5
—
—
—
0
0
20
68
3.04
4.78
1.1
1.3
—
—
—
0
0
20
68
3.04
4.78
1.1
1.3
—
412.50
—
0
8
125
867
1.64
4.77
5.0
4.1
1.02
1.02
kg/l
0.97
82
561
392
3665
3.55
4.68
17.6
12.1
26.00
26.40
u/l
0.21
387
3562
131
927
1.61
4.59
2.7
2.2
2.55
2.82
mg/l
0.74
115
798
25
99
2.63
4.56
1.4
1.2
—
—
—
0
0
395
3758
3.57
4.44
37.7
24.5
134.45
135.30
g/l
0.55
395
3721
395
3756
3.60
4.43
38.0
24.8
40.40
40.39
%
0.02
395
3717
395
3756
3.60
4.43
37.4
24.3
91.19
91.26
fl
0.12
395
3722
120
838
1.62
4.41
1.4
1.3
1.28
1.34
u/ml
0.03
31
233
44
228
2.04
4.36
4.4
6.4
24.74
24.28
mmol/l
0.34
44
220
360
3263
1.97
4.34
6.6
5.3
1.94
1.93
mu/l
0.04
345
2992
13
29
4.60
4.28
1.1
1.2
—
—
—
0
0
13
30
4.44
4.16
1.1
1.2
—
—
—
0
0
13
30
4.44
4.16
1.1
1.2
—
—
—
0
0
365
3334
2.01
4.14
7.3
6.5
39.48
39.42
mmol/mol
0.05
350
3123
123
877
1.58
4.10
1.8
1.6
1.41
1.42
mg/l
0.01
97
684
14
36
3.99
4.03
1.1
1.3
—
—
—
0
0
16
53
3.10
4.01
1.6
1.4
—
—
—
0
0
92
616
1.64
3.96
3.4
3.0
0.80
0.82
mmol/l
1.02
87
586
54
311
1.85
3.95
2.8
2.5
0.18
0.35
e6/l
1.12
47
300
12
28
4.38
3.84
1.1
1.3
—
—
—
0
0
109
769
1.57
3.77
2.9
2.9
2.46
2.45
mmol/l
0.24
100
694
92
625
1.61
3.73
3.6
3.1
3.92
2.42
e6/l
0.54
52
299
145
1094
1.51
3.68
4.2
3.2
0.42
0.51
e6/l
0.17
113
797
13
35
3.80
3.62
1.1
1.2
—
—
—
0
0
12
32
3.83
3.41
1.2
1.2
61.33
44.94
u/l
0.74
12
27
49
287
1.81
3.40
1.6
1.5
—
—
—
0
0
118
867
1.51
3.35
3.5
2.6
3.66
5.27
e6/l
1.46
111
794
24
109
2.28
3.32
1.6
1.3
—
—
—
0
0
91
633
1.57
3.31
2.9
2.4
12.77
12.95
umol/l
0.08
86
587
184
1480
1.45
3.30
4.8
3.8
0.02
0.03
estimate
0.14
41
346
145
1115
1.47
3.28
1.9
1.7
22.46
20.67
nmol/l
0.75
129
938
22
97
2.34
3.26
1.4
1.5
4865.86
18342.24
e6/l
1.20
14
68
158
1238
1.45
3.24
4.5
3.1
29.58
33.57
u/l
1.04
149
1171
8
15
5.42
3.20
1.6
1.3
99.25
94.93
%
—
8
15
33
173
1.99
3.20
3.2
4.4
1.89
1.48
%
1.38
33
166
22
98
2.32
3.19
1.5
1.5
—
—
—
0
0
17
67
2.61
3.17
1.5
1.5
—
—
—
0
0
25
120
2.15
3.05
3.1
4.6
1.11
3.12
ratio
—
10
70
243
2080
1.42
2.98
3.4
2.9
—
—
—
0
0
95
683
1.51
2.96
3.7
2.9
0.88
0.98
e6/l
0.12
54
356
8
17
4.78
2.93
2.8
2.6
1261.50
1370.65
u/ml
—
8
17
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
23
109
2.18
2.90
1.9
2.1
0.32
0.41
iu/ml
—
10
52
82
576
1.53
2.84
1.6
1.5
—
—
—
0
0
73
501
1.56
2.80
1.4
1.4
—
—
—
0
0
375
3530
1.90
2.78
6.9
6.0
2.60
2.71
mmol/l
1.70
360
3269
86
614
1.51
2.76
1.8
1.7
1177.62
1191.63
nmol/l
0.05
68
458
5
6
8.42
2.75
1.0
4.8
151.40
137.67
%
—
5
6
56
364
1.63
2.70
2.7
2.3
39.66
30.34
u/l
0.75
44
305
364
3402
1.72
2.70
6.1
5.3
5.97
5.97
mmol/l
0.01
342
3129
8
19
4.27
2.69
2.5
2.3
137.38
101.15
ng/l
—
8
19
19
86
2.27
2.68
1.4
1.5
—
—
—
0
0
198
1657
1.38
2.65
2.5
2.1
100.53
95.13
pmol/l
0.79
101
825
23
114
2.08
2.62
1.4
1.6
—
—
—
0
0
318
2890
1.48
2.60
34.1
20.7
331.79
332.34
g/l
0.45
318
2878
8
20
4.06
2.58
1.3
1.4
—
—
—
0
0
25
129
2.00
2.56
3.3
5.0
28.57
48.58
mg/l
0.63
20
110
25
129
2.00
2.56
3.3
5.0
34.13
107.16
mg/l
0.91
20
110
18
83
2.22
2.45
1.5
1.5
—
—
—
0
0
78
560
1.49
2.43
3.0
2.4
22.99
22.55
%
0.10
72
522
35
206
1.77
2.43
1.1
1.2
78.64
137.63
u/ml
—
9
86
41
253
1.69
2.42
2.1
1.5
—
—
—
0
0
175
1452
1.36
2.40
4.2
3.9
60.68
43.97
ng/l
0.25
127
1070
40
246
1.69
2.39
2.0
2.6
23.74
20.70
au/ml
—
5
21
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
5
8
6.31
2.38
1.0
1.1
127.80
114.00
%
—
5
8
7
17
4.17
2.37
2.6
1.9
—
—
—
0
0
367
3458
1.69
2.36
5.8
5.1
1.45
1.47
mmol/l
0.44
348
3197
139
1120
1.37
2.27
4.8
3.9
0.00
0.01
estimate
0.74
48
380
368
3476
1.68
2.26
6.0
5.2
4.49
4.64
mmol/l
2.17
351
3227
144
1173
1.35
2.18
3.3
2.6
56.85
64.71
u/l
0.64
136
1100
13
55
2.41
2.14
2.6
1.8
1.48
1.54
mmol/l
0.13
13
55
0
55
0.00
2.08
0.0
1.6
—
1.28
—
0
33
0
55
0.00
2.08
0.0
1.6
—
0.97
—
0
33
0
55
0.00
2.08
0.0
1.6
—
1.07
—
0
33
5
10
5.05
2.07
1.0
1.0
—
—
—
0
0
116
920
1.37
2.07
4.6
4.5
23.02
21.80
%
0.29
49
432
13
56
2.37
2.07
1.1
1.1
154.33
42.50
iu/ml
—
6
6
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
11
4.59
1.94
1.0
3.1
135.40
120.36
%
—
5
11
20
106
1.93
1.94
2.4
1.6
—
—
—
0
0
37
238
1.61
1.89
2.8
1.7
—
—
—
0
0
7
22
3.22
1.88
1.1
1.6
—
—
—
0
0
23
130
1.82
1.86
1.5
1.7
223.67
268.06
ug/l
0.27
23
121
191
1653
1.30
1.81
2.8
2.8
—
—
estimate
—
0
0
7
23
3.08
1.80
1.1
1.7
—
—
—
0
0
139
1155
1.31
1.78
5.8
5.3
2.30
2.67
ug/l
0.33
128
1046
16
81
2.02
1.77
1.3
1.4
—
—
—
0
0
6
18
3.37
1.75
1.2
1.1
—
—
—
0
0
20
111
1.84
1.72
1.1
1.3
—
—
—
0
0
263
2386
1.29
1.68
3.6
3.2
48.05
48.54
u/l
0.03
252
2247
18
99
1.86
1.60
1.3
1.3
—
—
—
0
0
7
26
2.72
1.58
1.1
1.6
—
—
—
0
0
11
51
2.19
1.52
2.0
1.5
32.55
31.71
pg
0.23
11
51
12
58
2.10
1.50
1.3
1.6
—
—
—
0
0
9
37
2.46
1.49
1.0
1.4
—
—
—
0
0
10
45
2.25
1.47
1.6
1.3
0.15
0.19
nmol/l
—
10
30
26
164
1.63
1.47
2.0
1.9
1.68
3.47
ug/l
0.41
26
151
20
118
1.73
1.44
1.6
1.6
—
—
—
0
0
9
39
2.34
1.44
1.6
1.3
—
—
—
0
0
24
150
1.64
1.41
1.6
1.5
0.25
0.30
mg/l
0.26
11
65
7
29
2.44
1.40
1.1
1.1
—
—
—
0
0
6
23
2.63
1.37
1.2
1.0
—
—
—
0
0
356
3403
1.40
1.35
25.2
15.8
78.89
79.58
ml/min/173m2
0.25
340
3169
125
1058
1.26
1.34
4.6
3.2
0.00
0.09
estimate
0.60
36
327
15
83
1.84
1.33
1.1
1.9
—
—
—
0
0
0
41
0.00
1.32
0.0
3.4
—
58.17
—
0
41
32
454
0.68
1.29
5.9
4.8
33.28
31.90
%
0.28
25
289
95
781
1.28
1.29
1.9
1.8
171429022.57
17835807.77
pmol/l
0.43
77
656
8
36
2.25
1.25
1.1
1.1
—
—
—
0
0
16
94
1.73
1.19
1.3
1.4
—
—
—
0
0
48
363
1.37
1.17
4.5
3.3
—
—
—
0
0
15
88
1.73
1.13
1.4
1.3
—
—
—
0
0
8
40
2.02
1.12
1.5
1.6
—
—
—
0
0
16
96
1.69
1.12
2.4
1.6
—
—
—
0
0
65
521
1.30
1.08
6.4
6.3
103.52
104.25
mmol/l
0.54
65
521
13
74
1.78
1.08
1.7
1.8
—
—
—
0
0
7
33
2.14
1.06
1.1
1.6
—
—
—
0
0
346
3320
1.30
1.04
4.8
4.3
1.29
1.30
mmol/l
0.04
327
3040
5
23
2.19
0.98
1.6
3.5
0.40
0.91
%
—
5
23
16
101
1.61
0.95
2.5
3.1
2.00
1.49
index
—
9
59
6
27
2.24
0.94
2.2
2.1
12.82
13.25
%
—
6
27
6
28
2.16
0.92
3.0
1.2
107.50
103.86
pmol/l
—
6
28
28
203
1.41
0.90
4.1
3.1
4.69
4.40
pmol/l
0.82
21
186
6
29
2.08
0.89
1.0
1.0
—
—
—
0
0
14
87
1.63
0.88
2.4
1.8
535.76
5.70
iu/l
—
6
36
26
189
1.40
0.83
3.7
3.5
1.02
1.02
ratio
0.10
26
178
8
47
1.72
0.81
1.4
1.2
300.63
345.93
pmol/l
—
8
41
8
47
1.72
0.81
1.0
1.1
—
—
—
0
0
10
58
1.74
0.80
1.1
1.2
1.48
1.49
g/l
—
10
52
0
25
0.00
0.79
0.0
1.0
—
—
—
0
0
14
90
1.58
0.79
1.2
1.1
—
4.48
—
0
15
25
184
1.38
0.76
6.7
2.8
24.53
58.19
u/ml
1.05
25
178
16
108
1.50
0.74
1.1
1.3
168.20
266.61
miu/ml
—
5
46
9
57
1.59
0.71
1.6
1.6
—
—
—
0
0
5
26
1.93
0.71
1.2
1.4
52.93
50.77
ug/l
—
5
26
14
201
0.69
0.66
7.4
3.7
48.92
49.46
%
0.02
14
196
12
79
1.53
0.63
1.3
1.2
7.71
6.97
e6/l
—
7
60
25
191
1.33
0.62
2.1
1.5
—
—
—
0
0
14
98
1.44
0.57
1.1
1.5
—
—
—
0
0
37
303
1.24
0.56
2.7
2.5
10.85
13.02
nmol/l
0.81
32
285
5
88
0.56
0.56
1.8
1.6
901.14
978.61
mu/l
—
5
68
6
38
1.59
0.54
1.3
3.1
550.00
765.71
mg
—
6
38
16
117
1.38
0.53
1.2
1.2
—
—
—
0
0
6
40
1.51
0.52
1.2
3.2
2.93
3.19
nmol/l
—
6
40
21
163
1.30
0.49
3.0
3.4
29.48
1337.89
u/ml
0.90
16
143
7
110
0.63
0.49
1.4
1.2
—
—
—
0
0
7
110
0.63
0.49
1.4
1.2
—
—
—
0
0
7
50
1.41
0.45
2.9
4.1
—
—
—
0
0
17
218
0.77
0.43
2.9
2.5
1.39
1.18
%
0.39
17
218
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
5
34
1.48
0.40
2.0
1.9
—
—
—
0
0
5
34
1.48
0.40
2.0
1.9
—
—
—
0
0
5
34
1.48
0.40
2.0
1.9
—
—
—
0
0
14
106
1.33
0.39
2.2
1.3
272.56
314.70
ug/g
—
7
68
5
35
1.43
0.39
4.2
1.5
232.00
303.00
mu/l
—
5
29
28
330
0.84
0.36
3.7
2.7
4.34
4.45
kpa
0.16
28
320
6
44
1.37
0.34
2.2
2.0
—
—
—
0
0
6
47
1.28
0.32
1.2
1.2
—
—
—
0
0
7
54
1.30
0.30
1.0
1.1
—
2.06
—
0
10
19
157
1.22
0.30
3.3
2.2
—
—
—
0
0
9
119
0.75
0.27
1.2
1.1
0.92
0.91
g/l
—
9
119
94
882
1.09
0.26
2.5
2.3
—
—
—
0
0
5
39
1.29
0.23
1.2
1.2
95.40
531.83
u/l
—
5
39
5
42
1.19
0.21
1.2
2.4
—
21.43
—
0
17
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
6
48
1.25
0.20
2.2
1.9
—
—
—
0
0
0
14
0.00
0.20
0.0
3.1
—
—
—
0
0
9
113
0.79
0.20
1.2
1.1
1.58
1.55
g/l
—
9
113
10
122
0.82
0.19
2.5
3.6
25.13
25.09
mmol/l
—
10
114
6
53
1.13
0.18
1.2
1.1
—
10.04
—
0
16
15
128
1.18
0.18
3.9
3.9
1.14
1.34
mmol/l
0.85
15
123
22
247
0.88
0.17
4.0
2.8
133.14
128.32
g/l
0.42
22
237
30
273
1.11
0.16
3.4
2.0
—
—
—
0
0
14
120
1.17
0.16
1.9
1.7
—
—
—
0
0
11
130
0.84
0.16
1.6
1.7
—
—
—
0
0
40
372
1.08
0.15
3.4
3.1
2.40
1.95
mmol/l
0.40
35
318
11
94
1.17
0.13
1.5
1.3
—
—
—
0
0
30
277
1.09
0.13
4.5
3.0
53.22
66.64
ml/min/173m2
—
9
129
14
123
1.14
0.12
3.6
2.2
—
—
—
0
0
12
135
0.89
0.10
1.7
1.9
—
—
—
0
0
5
46
1.09
0.09
1.2
1.2
—
—
—
0
0
40
421
0.94
0.09
10.6
6.5
—
—
—
0
0
42
439
0.95
0.08
1.9
1.7
1.66
1.49
%
0.64
36
374
8
91
0.88
0.07
1.1
1.5
—
—
—
0
0
37
385
0.96
0.06
3.6
3.1
5.92
5.74
kpa
0.61
37
373
34
352
0.96
0.04
2.4
2.1
3.44
3.53
ratio
0.16
29
292
29
300
0.96
0.03
3.4
2.1
—
—
—
0
0
25
259
0.96
0.02
2.1
1.8
3.11
3.53
mmol/l
1.26
19
199
41
401
1.02
0.02
4.5
4.5
6.31
9.41
ug/l
0.51
32
337
16
167
0.96
0.01
1.6
1.4
—
—
—
0
0
18
178
1.01
0.00
1.1
1.0
—
—
—
0
0
69
685
1.01
0.00
3.1
3.2
1.01
0.80
ug/l
0.65
44
436
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
1.18
—
0
9
5
51
0.98
-0.00
1.6
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
6.49
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PIGPURPDERM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PIGPURPDERM | 0.86 [0.69, 1.07] | 0.17 |
| Birth year | 0.995 [0.99, 1.0] | 0.213 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 992 females with L12_PIGPURPDERM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PIGPURPDERM | 1.032 [0.84, 1.26] | 0.763 |
| Birth year | 0.985 [0.98, 0.99] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 152 out of 884 males with L12_PIGPURPDERM died.
Mortality risk
Mortality risk for people of age
years, who have L12_PIGPURPDERM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.118% | 0.185% |
| 5 | 0.529% | 1.12% |
| 10 | 1.299% | 2.87% |
| 15 | 2.442% | 5.331% |
| 20 | 4.198% | 9.065% |
Relationships between endpoints
↥Index endpoint: L12_PIGPURPDERM – Pigmented purpuric dermatosis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data